Anika Therapeutics (ANIK) Misses Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.78 +2.06%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of ($0.13), $0.05 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $28.22 million versus the consensus estimate of $28.15 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Tier IV Inc (593A:JP) at Overweight
- UBS Upgrades Celestica (CLS) to Buy
- ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
